Microfluidic-based synthesized carboxymethyl chitosan nanoparticles containing metformin for diabetes therapy: In vitro and in vivo assessments

ABD

Industry: Nanomedicine
Like 0

Instrument: Vasco

Industry: Nanomedicine

DOI: https://doi.org/10.1016/j.carbpol.2021.117889

Keywords: Microfluidics, Nanoparticle, Metformin, Carboxymethyl chitosan, Drug delivery, Diabetes therapy

This work was aimed to synthesize novel crosslinked carboxymethyl chitosan nanoparticles (CMCS NPs) containing metformin hydrochloride (MET) using microfluidics (MF) and evaluate their performance for diabetes therapy. The field emission-scanning electron microscopy (FE-SEM) images and dynamic light scattering (DLS) results showed that the NPs average size was 77 ± 19 nm with a narrow size distribution. (351 characters)

Get in Touch

With a single and continuous measurement, VASCO KIN™ gives you access to all characterization data of your reaction (size distribution evolution over time).